Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- An Overview of Migraine
- Etiology and Pathophysiology
- Symptoms and Triggers
- Epidemiology
- Current Treatment
- Abortive Treatments
- Triptans
- Ergot Derivatives
- Prophylactic Therapies
- Beta Blockers
- NSAIDS
- Antiepileptic Agents
- Antidepressants
- 5-HT Antagonists
- Current Market
- Emerging Agents
- Abortive Therapies
- Pozen and GSK' s Trexima
- NovaDel' s Sublingual Sumatriptan
- Zogenix' s Subcutaneous Sumatriptan
- Alexza' s Prochlorperazine
- ProEthic' s Diclofenac
- Pozen' s Lornoxicam
- GlaxoSmithKline' s 274150
- GlaxoSmithKline' s 705498
- Boehringer Ingelheim' s Olcegepant
- Prophylactic Therapies
- Ariston' s AST-726
- Minster Pharmaceutical' s Tonabersat
- TorreyPines Therapeutics' Tezampanel
- Eisai' s E-2007
- Winston' s Zucapsaicin
- Market Outlook
- New Opportunities in the Migraine Market
- Generic Threats
- Outlook to 2010
Tables
- 1. Neurotransmitters and Biochemicals Implicated in Migraine Attacks
- 2. Leading Branded Prescription Treatments for Migraine, 2005
- 3. Products in Clinical Development for the Treatment of Migraine
Figures
- 1. Select Precipitating (Triggers) Factors Associated with Migraine
- 2. Time Course of Migraine Symptom Intensity and Recommended Treatments
- 3. Worldwide Triptan Market, 2005
|
Related Report
|
View Cart
